Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Eli Lilly

Founders Eli Lilly

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 56
Average round size
info
The average size of a deal this fund participated in
$50M
Portfolio companies 48
Rounds per year 0.38
Lead investments 13
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.14
Exits 17
Key employees 4

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

Eli Lilly appeared to be the Corporate Investor, which was created in 1876. The main office of represented Corporate Investor is situated in the Indianapolis. The fund was located in North America if to be more exact in United States.

The common things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Eli Lilly performs on 0 percentage points less the average number of lead investments. The high activity for fund was in 2016. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies.

Besides them, we counted 4 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Eli Lilly, startups are often financed by Skyline Ventures, SV Health Investors, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Innovation, ARCH Venture Partners, Watson Fund. In the next rounds fund is usually obtained by RTW Investments LLC, Zesiger Capital, Unilever Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Immunocore, Perlegen Sciences, ImmunoGen. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Biotechnology, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Eli Lilly:
Typical Co-investors
Eli Lilly is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Eli Lilly:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Air Liquide Ventures France, Ile-de-France, Paris
Alcumus Group Cardiff, United Kingdom, Wales
Allbrook & Company Minneapolis, Minnesota, United States
Capital6 Eagle -
Jozi Angels Gauteng, Johannesburg, South Africa
Leitmotiv Private Equity China, Hong Kong, Hong Kong Island
Los Angeles County Economic Development Corporation California, Los Angeles, United States
Mic Invest -
Ministry of Health Singapore Central, Central Region, Singapore
Modern Times Group (MTG) Stockholm, Stockholm County, Sweden
Orca Capital China, Shanghai
OTS Aichi Prefecture, Japan, Kasugai
REMUS Capital Boston, Massachusetts, United States
Rhon-Klinikum Bad Neustadt An Der Saale, Bavaria, Germany
SciClone Pharmaceuticals California, Foster City, United States
Startupbootcamp Scale San Francisco -
Teton Growth Partners Jackson, United States, Wyoming
VICTORIA Venture Capital SCR-Pyme S.A. Barcelona, Catalonia, Spain
Wadi Makkah Ventures Makkah Region, Mecca, Saudi Arabia
WDHB Colorado, Denver, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Rezo Therapeutics

Biotechnology
Product Research
$78M17 Nov 2022 South San Francisco, California, United States

Auron Therapeutics

Biotechnology
Health Care
Therapeutics
$48M20 Jul 2022 Massachusetts, United States

Artax Biopharma

Biopharma
Biotechnology
Therapeutics
$26M11 May 2022 Cambridge, Massachusetts, United States

Arkuda Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$64M10 Feb 2022 Cambridge, Massachusetts, United States

Iterative Scopes

Computer Vision
Health Care
Health Diagnostics
Medical
$150M19 Jan 2022 Cambridge, Massachusetts, United States

Verge Genomics

Bioinformatics
Biotechnology
Genetics
Health Care
Machine Learning
Neuroscience
Therapeutics
$98M16 Dec 2021 San Francisco, California, United States

Regor Therapeutics

Biotechnology
Medical
Pharmaceutical
$50M10 Dec 2021 Boston, Massachusetts, United States

Mozart Therapeutics

Biotechnology
$55M26 Oct 2021 -

GenEdit

Biotechnology
Delivery Service
Genetics
Therapeutics
$26M23 Sep 2021 Berkeley, California, United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Eli Lilly?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: